Literature DB >> 16556261

Extended sequence preferences for oligodeoxyribonucleotide activity.

Petar Lenert1, Adam J Goeken, Robert F Ashman.   

Abstract

Synthetic type B phosphorothioate oligodeoxyribonucleotides (ODN) activate mouse B cells via Toll-like receptor 9 (TLR9). Starting with closely related 15-mer prototype ODN, the sequence requirements for stimulatory (ST-) and inhibitory (IN-) activity were contrasted, by measuring apoptosis protection, G(1) entry and interleukin-6 secretion. ST-ODN and IN-ODN differ in that (1) ST-ODN require a 5' T, (2) the central CG is obligatory, (3) CG must be flanked 3' specifically by TT at the position where IN-ODN have GG, and (4) IN-ODN tolerate truncation of the 3' end better than ST-ODN. Features shared by ST-ODN and IN-ODN include (1) requiring CC adjacent to the 5' end, and (2) avoiding CC immediately 5' to the CG. This pattern is used to create a model of how ST-ODN binding might function to aggregate TLR9 so as to initiate the signal, and how the 5' ends of ST-ODN and IN-ODN compete for binding. Further justification for considering TLR9 to be the ODN receptor was provided by a demonstration that in HEK293 cells transfected with TLR9, the potency of a panel of ODN for activating NF-kappaB roughly parallels that seen in the biological assays in mouse B cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556261      PMCID: PMC1782261          DOI: 10.1111/j.1365-2567.2006.02320.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

2.  Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells.

Authors:  Petar Lenert; Wendy Rasmussen; Robert F Ashman; Zuhair K Ballas
Journal:  DNA Cell Biol       Date:  2003-10       Impact factor: 3.311

3.  Sequence requirements for oligodeoxyribonucleotide inhibitory activity.

Authors:  Robert F Ashman; J Adam Goeken; Jennifer Drahos; Petar Lenert
Journal:  Int Immunol       Date:  2005-03-03       Impact factor: 4.823

4.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  CpG motifs in bacterial DNA trigger direct B-cell activation.

Authors:  A M Krieg; A K Yi; S Matson; T J Waldschmidt; G A Bishop; R Teasdale; G A Koretzky; D M Klinman
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

Review 6.  Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications.

Authors:  Sandip K Datta; Hearn J Cho; Kenji Takabayashi; Anthony A Horner; Eyal Raz
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

7.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

8.  Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.

Authors:  Mark Rutz; Jochen Metzger; Tanja Gellert; Peter Luppa; Grayson B Lipford; Hermann Wagner; Stefan Bauer
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

9.  Simultaneous staining of ribonucleic and deoxyribonucleic acids in unfixed cells using acridine orange in a flow cytofluorometric system.

Authors:  F Traganos; Z Darzynkiewicz; T Sharpless; M R Melamed
Journal:  J Histochem Cytochem       Date:  1977-01       Impact factor: 2.479

10.  CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry.

Authors:  A K Yi; M Chang; D W Peckham; A M Krieg; R F Ashman
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

View more
  11 in total

Review 1.  Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

Authors:  Felipe von Glehn; Leonilda M Santos; Konstantin E Balashov
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

2.  Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Authors:  Robert F Ashman; J Adam Goeken; Petar S Lenert
Journal:  Int Immunopharmacol       Date:  2011-03-02       Impact factor: 4.932

3.  Structure-dependent modulation of alpha interferon production by porcine circovirus 2 oligodeoxyribonucleotide and CpG DNAs in porcine peripheral blood mononuclear cells.

Authors:  Frida Hasslung Wikström; Brian M Meehan; Mikael Berg; Sirje Timmusk; Josefine Elving; Lisbeth Fuxler; Mattias Magnusson; Gordon M Allan; Francis McNeilly; Caroline Fossum
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.

Authors:  Ilia N Buhtoiarov; Paul M Sondel; Jens C Eickhoff; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2006-12-08       Impact factor: 7.397

5.  Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding.

Authors:  Robert F Ashman; J Adam Goeken; Eicke Latz; Petar Lenert
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

Review 6.  Structural requirements and applications of inhibitory oligodeoxyribonucleotides.

Authors:  Robert F Ashman; Petar Lenert
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines.

Authors:  Tristan T Beaudette; Eric M Bachelder; Joel A Cohen; Allie C Obermeyer; Kyle E Broaders; Jean M J Fréchet; Eun-Suk Kang; Ines Mende; William W Tseng; Matthew G Davidson; Edgar G Engleman
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

Review 8.  Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus.

Authors:  Petar S Lenert
Journal:  Arthritis Res Ther       Date:  2006-01-10       Impact factor: 5.156

9.  Comparative Study of 5'- and 3'-Linked CpG-Antigen Conjugates for the Induction of Cellular Immune Responses.

Authors:  Katrin Kramer; Sarah L Young; Greg F Walker
Journal:  ACS Omega       Date:  2017-01-25

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.